CRDL Cardiol Therapeutics Inc. - Class A

Cardiol Therapeutics Inc is a clinical-stage biotechnology company developing therapies for inflammatory heart disease. The company has received approval to commence a Phase II/III clinical trial investigating its product, CardiolRx, in COVID-19 patients with history of cardiovascular disease. CardiolRx is a pharmaceutically produced, GMP certified, THC free (<10 ppm) oral cannabidiol formulation.

$1.48  +0.06 (4.23%)
As of 06/24/2022 16:00:00 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Drug Manufacturers—Specialty &
Index country:  Canada
Country of incorporation:  
IPO date:  01/10/2019
Outstanding shares:  61,927,999
Average volume:  189,801
Market cap:   $87,937,759
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
Valuation   (See tab for details)
PE ratio:   -13.97
PB ratio:   1.32
PS ratio:   1,435.63
Return on equity:   -41.50%
Net income %:   -40,170.45%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy